ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1768

The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study

Christopher Rooney1, Ian Jeffery2, Kulveer Mankia3, Mark Wilcox1 and Paul Emery4, 1University of Leeds, Leeds, United Kingdom, 24D Pharma plc, Cork, Ireland, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Anti-CCP, longitudinal studies, microbiome, rheumatoid arthritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including those with pre-clinical RA). Subsequently, a variety of gut bacteria have been implicated as a potential impetus in the development of RA, none more so than Prevotella copri. Using a comprehensively phenotyped prospective cohort of individuals at-risk of RA this work investigates whether P. copri overabundance is ubiquitous within the pre-clinical phases of RA, establishes microbiota associations with traditional RA risk factors and hypothesizes a timeline for microbial action within RA development.

Methods: Individuals at-risk of RA were defined by the presence of anti-cyclic citrullinated protein (anti-CCP) antibodies and new musculoskeletal symptoms without clinical synovitis. Individuals were sampled at baseline (n =124 participants, 30 of whom progressed to RA), and longitudinally (n = 19 participants, 5 RA progressors) at 5 time points over 15 months. At-risk individuals were compared to healthy controls (n = 22) and to individuals with new onset RA (n = 7). Taxonomic alterations of the gut microbiome were investigated using 16S rRNA amplicon sequencing, at both strain and genus level and confirmed using shotgun metagenomic DNA sequencing.

Results: RA progression at genus level was associated with modest changes in the gut microbiome, mainly affecting the Firmicutes and Proteobacteria phyla. A single Prevotellaceae strain was enriched in at-risk individuals compared to healthy controls (fig 1). P. copri strains demonstrate overall increased abundance with increasing anti-CCP levels and risk of progression (score based on symptomatology, HLA status, anti-CCP level and ultrasound findings), but display strain specific fluctuations with respect to early immune dysregulation, intestinal permeability, genetic risk and rheumatoid factor positivity (fig 2). Time series analysis suggests RA progression involves the development of an unstable low diversity microbiome that is characterised by the accumulation of RA associated pathobionts within the 10 months preceding RA (fig 3), which includes, but is not limited to P. copri. Functional analysis shows the NORA gut microbiome has increased abundance of pathways associated with amino acid metabolism. Healthy controls had decreased ornithine production, a precursor for citrulline.

Conclusion: These results confirm and expand the bacterial associations linked to RA progression, which involves multiple taxa at both genus and strain level and is associated with the underlying risk profile of an individual. As with previous literature, an overabundance of Prevotellaceae was identified in those at-risk of RA compared to healthy controls. Strain specific fluctuations appears to be the hallmark of Prevotellaceae associations within the RA at-risk phase. Future work will investigate how niche bacterial specialisation to the underlying risk profile may subsequently affect the abundance threshold required for a bacterial impetus in RA related autoimmunity.

Supporting image 1

Differentially abundant taxa between groups. Pairwise volcano plots of at-risk individuals, NORA and healthy controls, plotting Log2 fold change against -Log10 P value, coloured according to significance. Vertical line denotes adjusted P value threshold, horizontal line denotes 0.5 Log2 fold change. Shape denotes Prevotellaceae (PVT) or not Prevotellaceae (NPVT) taxa.

Supporting image 2

Prevotellaceae chord plot. Associations of Prevotellaceae strains reaching nominal significant from adjusted DESeq2 models. Metadata variables in grey and strains designated by colour. Outer border denotes direction of association, increased abundance in red or decreased abundance in black.

Supporting image 3

Pairwise Bray-Curtis dissimilarity boxplots. (A) Boxplots of individual Bray-Curtis dissimilarities between gut microbiome sampling. Individuals progressing to RA plotted in the first row, with Bray-Curtis dissimilarity index coloured in red. Note, participant 3, has two points plotted which overlap significantly. (B) Boxplot of pairwise Bray-Curtis dissimilarities grouped according to time to new onset RA (NORA), or time from baseline non-progression (NP) sample.


Disclosures: C. Rooney: None; I. Jeffery: 4D Pharma plc, 3; K. Mankia: Abbvie, 6, Eli Lilly, 5, Galapagos, 6, Gilead, 5, Serac Lifesciences, 6; M. Wilcox: None; P. Emery: Boehringer Ingelheim, 2, Eli Lilly, 2, Novartis, 2.

To cite this abstract in AMA style:

Rooney C, Jeffery I, Mankia K, Wilcox M, Emery P. The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-dynamics-of-the-gut-microbiome-in-rheumatoid-arthritis-susceptibility-a-cross-sectional-and-longitudinal-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-dynamics-of-the-gut-microbiome-in-rheumatoid-arthritis-susceptibility-a-cross-sectional-and-longitudinal-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology